Shota Miyake

Kanagawa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.

Anti-IL-6 Receptor Antibody Suppresses Visual Dysfunction in AQP4 Peptide-Immunized Mice.

Journal: Translational vision science & technology

Published: February 05, 2026

Serum from patients with MuSK antibody-positive myasthenia gravis triggers transcriptomic changes leading to muscle atrophy and weakness in human myotube cells.

Serum from patients with MuSK antibody-positive myasthenia gravis triggers transcriptomic changes leading to muscle atrophy and weakness in human myotube cells.

Journal: Journal of neuroimmunology

Published: June 18, 2025

Serum from patients with acetylcholine receptor antibody-positive myasthenia gravis triggers pathogenic changes in human myotube cells.

Serum from patients with acetylcholine receptor antibody-positive myasthenia gravis triggers pathogenic changes in human myotube cells.

Journal: Journal of neuroimmunology

Published: June 13, 2025

Aquaporin-4 Peptide Injection in Mice Induces Retinal and Optic Nerve Alterations That Simulate Those of Neuromyelitis Optica Spectrum Disorder.

Aquaporin-4 Peptide Injection in Mice Induces Retinal and Optic Nerve Alterations That Simulate Those of Neuromyelitis Optica Spectrum Disorder.

Journal: Translational vision science & technology

Published: June 10, 2025

Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.

Anti-IL-6R antibody treatment changes microglial phenotype in AQP4 peptide-immunized mice, leading to suppression of myelitis severity.

Journal: Journal of neuroimmunology

Published: January 15, 2025

Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density.

Anti-IL-6 receptor antibody suppresses onset of paralytic symptoms in AQP4 peptide-immunized mice without lowering bone strength or mineral density.

Journal: Journal of neuroimmunology

Published: December 03, 2024

IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model.

IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model.

Journal: Frontiers in neurology

Published: December 15, 2023

Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.

Intradermal AQP4 peptide immunization induces clinical features of neuromyelitis optica spectrum disorder in mice.

Journal: Journal of neuroimmunology

Published: February 03, 2023

Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders.

Interleukin-6: evolving role in the management of neuropathic pain in neuroimmunological disorders.

Journal: Inflammation and regeneration

Published: May 31, 2021

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.

New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: January 28, 2021

Unisexual hybrids break through an evolutionary dead end by two-way backcrossing.

Unisexual hybrids break through an evolutionary dead end by two-way backcrossing.

Journal: Evolution; international journal of organic evolution

Published: April 18, 2019

Allergin-1 Immunoreceptor Suppresses House Dust Mite-Induced Allergic Airway Inflammation.

Allergin-1 Immunoreceptor Suppresses House Dust Mite-Induced Allergic Airway Inflammation.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: February 13, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026